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Plant-derived phytonutrients have emerged as health enhancers. Tocotrienols from
the vitamin E family gained high attention in recent years due to their multi-targeted
biological properties, including lipid-lowering, neuroprotection, anti-inflammatory,
antioxidant, and anticancer effects. Despite well-defined mechanism of action as an
anti-cancer agent, their clinical use is hampered by poor pharmacokinetic profile and
low oral bioavailability. Delivery systems based on nanotechnology were proven to
be advantageous in elevating the delivery of tocotrienols to tumor sites for enhanced
efficacy. To date, preclinical development of nanocarriers for tocotrienols include
niosomes, lipid nanoemulsions, nanostructured lipid carriers (NLCs) and polymeric
nanoparticles. Active targeting was explored via the use of transferrin as targeting ligand
in niosomes. In vitro, nanocarriers were shown to enhance the anti-proliferative efficacy
and cellular uptake of tocotrienols in cancer cells. In vivo, improved bioavailability of
tocotrienols were reported with NLCs while marked tumor regression was observed
with transferrin-targeted niosomes. In this review, the advantages and limitations of
each nanocarriers were critically analyzed. Furthermore, a number of key challenges
were identified including scale-up production, biological barriers, and toxicity profiles.
To overcome these challenges, three research opportunities were highlighted based
on rapid advancements in the field of nanomedicine. This review aims to provide a
wholesome perspective for tocotrienol nanoformulations in cancer therapy directed
toward effective clinical translation.
Keywords: tocotrienols, nanotechnology, drug delivery, cancer, nanoformulation
Abbreviations: AP, ascorbyl palmitate; AUC, area under the curve; CARPA, complement activation-related pseudo allergy;
Cmax, maximum serum concentration of the administered drug; CMC, chemistry, manufacturing and control; CXCR4,
C-X-C chemokine receptor type 4; DSC, diﬀerential scanning calorimetry; EGF-dependent PI3K, epidermal growth
factor-dependent phosphatidylinositol-3-kinases; EMT, epithelial–mesenchymal transition; EPR, enhanced permeability
and systems; FDA, Food and Drug Administration; ISO, International Organizations for Standardization; MMP-9, matrix
metallopeptidase-9; NCL, Nanotechnology Characterization Laboratory; NLCs, nanostructured lipid carriers; NMR, nuclear
magnetic resonance; OECD, Organization for Economic Co-operation and Development; p21, cyclin-dependent kinase
inhibitor 1; p27, cyclin-dependent kinase inhibitor 1b; PIT, phase inversion temperature; PLGA, poly(lactic-co-glycolic) acid;
RES, reticuloendothelial system; TGF-β, transforming growth factor-beta; Tmax, time taken to achieve maximum serum
concentration of the administered drug; VEGF, vascular endothelial growth factor; VEGFR-2, vascular endothelial growth
factor receptor 2.
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INTRODUCTION
Plant-derived phytochemicals played a pivotal role in
the development of cancer therapeutics. Many anti-
cancer agents used in clinical practice are derived from
natural phytochemicals (e.g., camptothecin and paclitaxel)
but they are highly associated with life-threatening
toxicities (Iqbal et al., 2017). As such, recent paradigm
shifts in cancer research led to global interest on new
phytochemicals as adjuvant therapy such as epigallocatechin-
3-gallate, curcumin, vanilloids, ﬂavones, jerantinine, and
vitamin E (Lemarié et al., 2012; Chung et al., 2017;
Soo et al., 2017; Mai et al., 2018). These natural therapeutics
often have lower potency compared to conventional
chemotherapeutics but are favored due to their low toxicity
proﬁles.
Vitamin E is a family of compounds consisting two
major groups, i.e., tocopherols and tocotrienols. They are
diﬀerentiated by the amount of saturation on the side
chains, each having four homologs (α, β, γ, δ). Although
the physiological role of α-tocopherol is well-established, little
is known about the nutritional mechanisms of tocotrienols.
The anti-cancer properties of tocotrienols were reported
in multiple cancer cell lines including breast, lung, liver,
pancreatic, and bladder cancers (Shun et al., 2004; Husain
et al., 2011). Tocotrienols were reported to target the
hallmarks of cancer via pro-apoptotic (caspase-8, Bid, Bax,
mitochondrial membrane permeability), modulation of
growth factors (EGF-dependent PI3K pathway, TGF-β),
cell cycle arrest (cyclin D1, p21, p27), anti-angiogenesis
(VEGF, VEGFR-2) and anti-metastatic properties (E-
cadherin, MMP-9, EMT, CXCR4) (Samant and Sylvester, 2006;
Hanahan and Weinberg, 2011; Nazzal and Sylvester, 2012;
Lim et al., 2014; Ye et al., 2015; De Silva et al., 2016;
Xun et al., 2017).
Despite active research, global recognition of tocotrienols
is still lacking, due to their low abundance in food sources.
While tocopherols are mainly found in soy bean and
sunﬂower oil, tocotrienols can be found in palm oil and
rice bran oil (Nesaretnam, 2008). Besides, the plasma
concentration of palm tocotrienols was detected at a much
lower concentration compared to that of tocopherols
(Patel et al., 2012), with a short half-life of 4 h (Tasciotti
et al., 2008). When investigated in rats, the absolute oral
bioavailability of tocotrienols was found to be less than 30%
for α-tocotrienol and less than 10% for γ- and δ-tocotrienol
(Yap et al., 2003).
One of the strategies to overcome their low oral bioavailability
is the application of nanotechnology. Due to their small size
and high surface area, nanomedicine exhibit key diﬀerences
in comparison to bulk materials, which were observed in
the context of solubility, pharmacokinetics, eﬃcacy, and
toxicity proﬁles (Ventola, 2017). In this review, we aim
to discuss the important similarities and diﬀerences among
nanoformulations that were investigated on tocotrienols, and
hence their challenges and opportunities toward clinical
application.
APPLICATION OF NANOFORMULATIONS
FOR TOCOTRIENOLS
As shown in Figure 1, four types of nanoformulations had been
studied for tocotrienols, i.e., niosomes, nanoemulsions, NLCs,
and polymeric nanoparticles.
Niosomes
Niosomes are bilayer vesicles made of non-ionic surfactants
and cholesterol. As depicted in Figure 1A, tocotrienols were
entrapped in unilamellar and multilamellar niosomes prepared
using Span 60 and AP (Fu et al., 2009; Tan et al., 2017).
Multilamellar vesicles were recorded with higher entrapment
eﬃciency (48.6 ± 1.7%) than unilamellar vesicles (28.5 ± 1.9%)
owing to the multiple lipid bilayers (Fu et al., 2009, 2011). In
cancer cells from human epithelial, brain and ovarian origin,
niosomes improved the anti-proliferative activity of tocotrienols
by at least 17-fold (Fu et al., 2009, 2011; Karim et al., 2017).
In breast cancer cells however, AP-based niosome showed
enhanced eﬃcacy of 3.4-fold compared to free tocotrienols
(Tan et al., 2017).
In addition, surface modiﬁcation of niosomes with transferrin
was investigated as an active targeting strategy. Being an iron
transporter, transferrin was widely investigated as a targeting
ligand, able to recognize overexpressed transferrin receptors in
various cancer cells (Dufès et al., 2000). In vivo, intravenous
injection of transferrin-bearing niosomes entrapping tocotrienol
led to 60% tumor regression on mice bearing A431 epidermoid
carcinoma tumors (Fu et al., 2009). By contrast, tumors from
other treatment groups were progressive. This eﬀect was further
improved with increasing duration of treatment (from 10 to
20 injections) resulting in 20% complete disappearance of the
tumors and 20% tumor regression at the end of the experiment
(Fu and Dufès, 2014). Similarly, in B16F10 murine melanoma
tumor models, the intravenous administration of tocotrienols
entrapped in transferrin-bearing niosomes led to 50% complete
disappearance of the tumors (Fu and Dufès, 2014). It was the
ﬁrst time that a tocotrienol formulation was shown to decrease
and even fully eradicate a tumor. In a further study, transferrin-
bearing multilamellar vesicles entrapping α-tocotrienol led to
complete tumor eradication of up to 60% of B16F10 tumors
(Karim et al., 2017).
Nanoemulsions
Nanoemulsions are thermodynamically stable dispersion of
two immiscible phase with droplets in the submicron size.
Surfactants were selected based on hydrophilic lipophilic
balance of the two phases, while method of preparation
was chosen among high energy processes that are able to
produce stable nanoemulsions. High pressure homogenization
(Alayoubi et al., 2013), microﬂuidization (Goh et al., 2015; Hasan
et al., 2018), and PIT emulsiﬁcation (Pham et al., 2016) were
studied, each having distinctive advantages. For example, narrow
size distribution was observed in nanoemulsions prepared using
microﬂuidization with increasing pressure and number of cycles
(Goh et al., 2015). Hybrid of more than 1 method (e.g., PIT
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FIGURE 1 | Types and physical characteristics of tocotrienol nanoformulations. (A) Niosomes, (B) nanoemulsions, (C) nanostructured lipid carriers, and (D)
polymeric nanoparticles.
and homogenization) was shown to produce nanoemulsion that
remained stable after 2 months’ storage (Pham et al., 2016).
When investigated in skin carcinomas, tocotrienol
nanoemulsions reported a higher anti-proliferative eﬀect
(IC50 in A431 and SCC-4 cells: 43 and 47 µM) compared to
tocotrienols/propyleneglycol mixture (IC50 in A431 and SCC-4
cells: 217 and 279 µM) (Pham et al., 2016). The anti-proliferative
activity of tocotrienol nanoemulsion was also proven in human
breast cancer cells (MDA-MB-231 and MCF-7) with IC50 of
7 and 14 µM respectively (Alayoubi et al., 2013). Although
in vivo data is limited, irritancy tests on reconstructed human
epidermis and human corneal epithelium models were studied
(Hasan et al., 2018). At 5% concentration, nanoemulsions were
classiﬁed as non-irritants to the eyes and skin according to
OECD guidelines.
Nanostructured Lipid Carriers (NLCs)
Nanostructured lipid carriers are solid colloidal dispersions
prepared by mixing a blend of solid and liquid oil matrix (Li
et al., 2017). Combination of lipids with low and high melting
points creates imperfections in the crystalline lipid core of
the NLCs that provide loading capacity for the incorporated
compounds (Muller et al., 2002). This property is advantageous
for lipophilic compounds such as tocotrienols, where loading
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FIGURE 2 | (A) Challenges and opportunities of tocotrienol nanocarriers in clinical translation. (B) Stumbling blocks of nanocarriers to reach tumors classified into
four major obstacles, i.e., stability in systemic circulation, RES, extravasation into tumor interstitium, and intracellular uptake.
capacity was shown in NLC using DSC and NMR techniques
(Ali et al., 2010a).
When tested in malignant ++SA cells, tocotrienols-loaded
NLCs were 12-fold more eﬃcacious (IC50: 1.50 ± 0.12 µM)
than α-tocopherol-loaded NLCs (IC50: 17.70 ± 0.74 µM)
(Ali et al., 2010b). Likewise, the anti-proliferative activities
were further enhanced with concurrent delivery of
simvastatin/tocotrienols in NLCs (IC50: 0.52± 0.02µM). In vivo,
pharmacokinetic proﬁles of tocotrienol were investigated in rats
after oral administration of lipid nanoparticles at 10 mg/kg body
weight (Abuasal et al., 2012). Based on plasma concentrations
over 12 h, the AUC and Cmax were approximately three times
higher when delivered in lipid nanoparticles compared to mixed
micelles. Furthermore, the onset of absorption is faster in lipid
nanoparticles, i.e., Tmax of 3 vs. 5 h for mixed micelles.
Polymeric Nanoparticles
Polymeric nanoparticles are commonly constructed using
amphiphilic polymers with two or more polymer chains of varied
hydrophobicity, having the ability to form self-assembledmicelles
in the presence of aqueous solution (Mir et al., 2017). A hybrid
system using poly(lactic-co-glycolic) acid (PLGA) and chitosan
was prepared by synthesizing PLGA-tocotrienol copolymer
(Alqahtani et al., 2015). In breast cancer cells, the cellular uptake
of tocotrienols was more than twofold higher when delivered
using hybrid nanoparticles compared to mixed micelles. In
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correlation, the anti-proliferative activity of tocotrienols inMDA-
MB-231 cells were enhanced by 25%when encapsulated in hybrid
polymeric nanoparticles compared to PLGA nanoparticles.
CHALLENGES
From a formulation point of view, enhanced eﬃcacy was
observed when tocotrienols were delivered using nanocarriers,
irrespective of the types. Nevertheless, the average success rate
of a novel therapeutic to travel from Phase 1 trial to regulatory
approval is merely 10% (Hay et al., 2014). To bridge the gap,
we identiﬁed three major challenges for clinical translation of
tocotrienol nanocarriers as depicted in Figure 2A.
Scale-Up Production
Among the tocotrienol nanocarriers reported here,
nanoemulsions were prepared using top–down method
whereas niosomes, NLC, and polymeric nanoparticles were
prepared using bottom–up techniques. For nanoemulsions,
high energy processes are required to achieve stability against
coalescence, creaming, and Ostwald ripening (Cinar, 2017). In
bottom–up methods, nanocarriers were formed by self-assembly
of their respective building blocks, controlled by the growth
or nucleation of lipids and polymers used (Robertson et al.,
2016). Concise control over the growth of building blocks
is signiﬁcantly hindered during scale-up production. Hence,
batch to batch variation tends to be high for nanoformulations
prepared using bottom–up methods such as silica nanoparticles
(diameter ranging from 32 to 160 nm between eight batches)
(Mulhopt et al., 2018). In addition, variation in mixing method,
time and solvent properties during scale-up production strongly
deﬁnes the size distribution of nanoformulations (Valencia et al.,
2012). Size distribution has a direct correlation with storage
stability due to its implication on the rate of agglomeration
and sedimentation of particles (Izak-Nau et al., 2015). Among
the nanocarriers discussed, freeze-dried technique was used for
niosomes and polymeric nanoparticles. Niosomes in freeze-dried
powder remained stable retainingmore than 85% of encapsulated
tocotrienols after 2 months’ storage (Tan et al., 2017). Besides,
NLC was reported to be stable for 6 months as dispersion at room
temperature, whereas nanoemulsions was stable up to 28 days at
4◦C (Nazzal and Sylvester, 2012; Goh et al., 2015).
For eﬃcient scale up production, continuous synthesis
systems were explored (Betke and Kickelbick, 2014). In
a continuous microﬂuidic system, reaction kinetics and
formulation composition can be controlled via manipulation of
the relative ﬂow rate (Lu et al., 2016). In fact, these devices have
been used to synthesize organic and inorganic nanoparticles and
were thoroughly reviewed in Valencia et al. (2012).
Biological Barriers
As illustrated in Figure 2B, there is a need for nanocarriers
to cross multiple biological barriers before reaching tumors.
Prolonged residence time in the systemic circulation is a major
challenge for nanomedicine due to the rapid sequestration
by macrophages and the RES. Stealth or long circulating
nanocarriers can be prepared using hydrophilic polymers.
Solulan and TPGS were investigated for niosomes while
Poloxamer 188 was investigated for nanoemulsion and NLC.
Upon hydration with ﬂuid, a thick polymer coat that forms
around the nanocarriers (Kumar and Rajeshwarrao, 2011) creates
steric repulsion thatminimizes the interaction withmacrophages,
thus extending the residence time of vesicles in the systemic
circulation (Wilhelm et al., 2016).
During vascular extravasation, most tocotrienol nanocarriers
exploit the EPR eﬀect or passive targeting. The EPR eﬀect enables
nanoparticles to be extravasated from systemic circulation to
tumor site through disorganized tumor vasculature and retained
in the tumor interstitium owing to poor lymphatic drainage
(Bazak et al., 2014). However, clinical translation of passively
targeted nanoparticles are hindered by heterogeneity of the EPR
eﬀect between and within cancer types. Tumor vascularity does
not only diﬀer in cancer types but in primary and metastatic
tumors of same type of cancer (Prabhakar et al., 2013). To
overcome this limitation, active targeting was reported as a
strategic method. To this end, niosome was investigated for
active targeting using transferrin as a ligand, showing up to 60%
of tumor eradication. Indeed, in a multivariate analysis of 117
studies on nanoparticles tumor delivery, active targeting showed
signiﬁcantly correlation with delivery eﬃciency compared to
passive targeting (Wilhelm et al., 2016).
At the cellular level, although positively-charged nanosystems
have higher cellular uptake (Patiño et al., 2015), nanocarriers
with negative zeta potential tend to minimize non-speciﬁc
internalization from negatively charged cell membrane (Karim
et al., 2017). Among the tocotrienol nanocarriers, niosomes,
nanoemulsions and NLC are negatively-charged, whereas hybrid
polymeric nanoparticles are positively-charged. Analysis by
Wilhelm et al. (2016) reported a direct relationship between
intracellular uptake and nanocarrier surface charge where highest
uptake was recorded for carriers with zeta potential above
+10 mV. In agreement, chitosan-grafted PLGA nanoparticles
bearing zeta potential of 12.2 ± 3.1 mV were shown to
accumulate in Caco2 colon cancer cell at 3.5-fold higher
compared to naked PLGA particles which are negatively charged
(−4.9 ± 1.8 mV) (Alqahtani et al., 2015). In a review by Blanco
et al., an ideal system would be one that bears a neutral or
slightly negative charge in blood circulation, and functionalized
to switch to positive surface charge upon contact with tumor cells
to facilitate internalization (Blanco et al., 2015). To achieve this,
Yuan et al. (2012) investigated the use of zwitterion polymers that
carry reversible surface charges at diﬀerent pHs.
Safety
The safety proﬁle of a drug can be dramatically shifted
when delivered in nanocarriers. For example, the known
cardiotoxicity of doxorubicin was markedly reduced when
delivered in liposomes accompanied with an increased incidence
of hematological toxicity and palmar–plantar erythrodysesthesia
(Lorusso et al., 2007; Raﬁyath et al., 2012; Rom et al., 2014).
In general, due to preferential accumulation in the RES
system, symptoms associated with kidney and liver toxicity are
major concerns for nanocarriers. In addition, immunological
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reaction to nanomedicine, speciﬁcally the CARPA has been
widely reported. In a comprehensive review, clinical events
of CARPA were previously reported in liposomes, micellar,
polymer-based and protein-based nanocarriers (Szebeni, 2014).
Material selection was shown to be a major determinant for
biocompatibility and strongly diﬀerentiates the toxicity proﬁle
of nanocarriers. Materials such as lipids used in niosomes and
NLC are naturally more biocompatible compared to inorganic
materials and carbon-based delivery systems (Ventola, 2017). In
a nutshell, nanotoxicity is governed by multiple factors where
increased complexity of a nanocarrier will inevitably complicate
its toxicity proﬁle.
Due to the lack of harmonized protocols in nanotoxicity
studies, in vivo toxicity data of tocotrienol nanocarriers were
largely dependent on examination of animal wellness and
behavior (Fu et al., 2009; Karim et al., 2017). In fact, in vivo
data of tocotrienol nanocarriers to date are fairly limited. For
example, pharmacokinetic proﬁles were only available for NLCs
and remain critically in need for nanocarriers (Abuasal et al.,
2012). Besides, the percentage of injected dose in tumors has
not been quantiﬁed in tocotrienols delivered using nanocarriers.
To this end, novel development in image-guided studies with
labeled-tocotrienols can be exploited.
OPPORTUNITIES
Despite signiﬁcant challenges, more than 50 nanodrugs have
received FDA approval and being used in clinical practice (Bobo
et al., 2016). A big proportion of these nanopharmaceutics are
indicated for cancer, antimicrobial drugs and bone substitutes
to name a few (Ventola, 2017). When categorized according
to types, liposomes, polymeric nanoparticles and nanocrystals
dominated the list, while there is an increasing trend of
metallic and micelle-based nanodrugs undergoing clinical trials
(Bobo et al., 2016). Among the tocotrienol nanocarriers that
we have analyzed in this review, lipid vesicles and polymeric
nanoparticles are more familiar to the industry whereas NLC
and nanoemulsions are the emerging nanocarriers slowly gaining
recognition in the market. Nevertheless, considering the market
prospect of nanodrugs valued at USD 178 billion complemented
by the estimated market share of natural products valued over
USD 200 billion, opportunities lie in the hands of market-
driven research (Ventola, 2017). In this section, several research
opportunities for tocotrienol nanocarriers are outlined.
Combination With Chemotherapeutics
To overcome the compromised eﬃcacy of natural products,
adjuvant therapy in combination with chemotherapeutics is an
attractive strategy. For example, combination of curcumin and
docetaxel in breast cancer patients is currently being studied
in a phase-2 clinical trial (NCT00852332). It was suggested
that combination of phytochemicals with anticancer agents may
potentially increase the eﬃcacy of the cancer drugs and reduce
the overall toxicity (Er et al., 2018). Speciﬁcally, Eitsuka et al.
(2016) comprehensively reviewed combination of tocotrienols
with chemotherapeutic agents, where synergistic eﬀect was
observed when combined with statins, celecoxib, and geﬁtinib.
To ensure consistent concurrent delivery of tocotrienols-drug
combinations, drug delivery systems including nanoemulsions
and NLC were investigated. In a study with simvastatin and
tocotrienols nanoemulsion, lower IC50 values in MDA-MB-231
(4.9 µM) and MCF-7 cells (10.3 µM) were observed compared
to simvastatin alone in MDA-MB-231 (8 µM) and MCF-7 cells
(19 µM) (Alayoubi et al., 2013). Co-loading of tocotrienols and
curcumin in nanoemulsion also showed synergistic anticancer
eﬀects in human breast (MCF-7) and ovarian (OVCAR-8)
cancer cells (Steuber et al., 2016). In NLC, Ali et al. (2010b)
reported 65% lower in IC50 values with concurrent delivery of
simvastatin/tocotrienols than tocotrienols alone in +SA. Indeed,
delivery of a consistent ratio of combinatory drugs is crucial
to maintain the synergistic eﬀect. In a review by Zhang et al.
(2016), the rationale and advantages of various nanocarriers were
discussed.
Disease-Driven and Patient-Focused
Design
The potentials of EPR-based nanomedicine are hampered by the
complexity of cancer types that practically limits the eﬃcacy.
Early understanding on the behavior of nanomedicines in tumors
as a disease-derived approach is crucial (Hare et al., 2017). In
recent years, computational methods or simulated tools to obtain
detailed view of nanocarriers-organs interactions during their
transport to tumors have become increasingly popular. Kiew
et al. (2017) and Ho et al. (2018) investigated the permeability
of nanocarriers in vitro using biomimetic microﬂuidic models.
These techniques enabled preliminary assessment on the delivery
eﬃciency of nanocarriers, which can provide a feedback system
to formulation studies. The diﬀerential levels of a nanodrug
present in tumor tissues compared to normal tissues determine
its safety proﬁle. In a patient-focused approach, in vivo models
which are clinically relevant shall be developed to assess
the distribution of nanomedicine. For a clinically relevant
model, multiple characteristics are highlighted including stromal
morphology, tumor architecture and vessel distribution (Hare
et al., 2017). Such models can be developed using patient-
derived tumor explant models and genetically engineered mouse
models (Ruggeri et al., 2014). For nanotherapeutics that are
actively-targeted, the eﬀectiveness of targeting ligand depends
on the aﬃnity of the ligand toward its receptor and number
of receptors expressed in the cancer cells (Fahmy et al., 2005).
Therefore, patient selection via receptor pre-screening oﬀers
potential advantage in the prediction of treatment outcome.
Regulatory Guidelines
Based on CMC approach, regulatory measures on a global
scale are playing important roles in the control mechanism
of nanomedicines (Havel et al., 2016). A number of
technical speciﬁcations published from ISO nanotechnology
technical committee 229 described standardized methods for
characterization of nanoformulations. From the industry’s
perspective, there was a pressing need on FDA guidelines due to
the lack of convergent deﬁnition of “nanoscale”. In 2014, FDA
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published three guidelines on the human use of nanomedicine.
Working in synchronicity, the NCL was formed in 2004 and
has since conducted studies on more than 300 nanoformulations
(Tinkle et al., 2014). Another laboratory in Europe, NCL is
oﬀering similar partnerships with scientists and pharmaceutical
companies. With these regulations in place, early consultation
was made possible where research design can be structured
toward regulatory clearance as one of the steps for eﬃcient
clinical translation.
CONCLUSION
In this review, nanotechnology was proven to be an eﬃcient
tool in enhancing the delivery and eﬃcacy of tocotrienols.
When delivered in nanoformulations, tocotrienols showed
more than 10-fold improvement in their anti-proliferative
eﬃcacy while animal studies reported up to 60% of complete
tumor disappearance using tumor-targeted nanocarriers.
Nevertheless, there are several challenges to overcome for
clinical translation including scale-up production, multiple
biological barriers and safety characterization. Abiding to the
quote by Albert Einstein, “In the middle of every diﬃculty
lies opportunity”. Potential research opportunities highlighted
in this review were combination strategy, disease-driven and
patient-focused study design as well as emerging regulatory
guidelines. Using nanotechnology for eﬀective delivery,
tocotrienols can potentially be the next medicine for cancer
therapy.
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